Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Results of Operations and Financial Performance
COR logo

Cencora Specialty Sales Surge 23% Driven by GLP-1 Demand and $7.4 Billion OneOncology Deal

COR10-QFiling Date: 5/6/2026
Cencora, Inc.
Description

What this story covers

Cencora reports 3.8% revenue growth to $78.4 billion, fueled by a 23% surge in specialty and GLP-1 products. Despite $12.4 billion in debt and $4.3 billion in opioid-related liabilities, the company maintains strong liquidity and effective internal controls.

Story snapshot

CompanyCencora, Inc.
TickerCOR
VariantStandard detailed
Duration12:09
Filing type10-Q
PeriodQ4 2026
IndustryHealthcare & Pharmaceuticals
Accession0001140859-26-000020
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in